Interactive Brokers: Volatility Is Supercharging Commercial Momentum — Positive

IBKR   Seeking Alpha — May 26, 2025

IBKR capitalizes on market volatility, with Trump's tariff announcement sparking surges in trading activity, DARTs, and new account growth. Q1 2025 results exceeded expectations: adjusted net revenues up 15% YoY, pretax margin at 73%, and strong operating leverage. April metrics highlight momentum: 3.7 million accounts (+32% YoY), 3.8 million DARTs (+63% YoY), and $133 billion in client credit balances.

image for news Interactive Brokers: Volatility Is Supercharging Commercial Momentum

AGNC Vs STWD: Which mREIT Has Stronger Income Potential? — Positive

AGNC  STWD   Zacks Investment Research — May 26, 2025

AGNC Investment's proactive hedging, stable Agency MBS income and 16.29% dividend yield give it an edge over Starwood Property.

image for news AGNC Vs STWD: Which mREIT Has Stronger Income Potential?

NIO vs. TSLA: Which EV Stock Has More Charge for the Future? — Negative

NIO  TSLA   Zacks Investment Research — May 26, 2025

NIO and Tesla face challenges, but one seems better placed now. We break down what drives each and which EV stock deserves your attention today.

image for news NIO vs. TSLA: Which EV Stock Has More Charge for the Future?

UAL Seals Pivotal Deal With Flight Attendants, Uplifts Outlook — Positive

UAL   Zacks Investment Research — May 26, 2025

United Airlines reaches a tentative deal with flight attendants, offering top-tier pay, bonuses and scheduling gains for 28,000 crew over five years.

image for news UAL Seals Pivotal Deal With Flight Attendants, Uplifts Outlook

MRK Down 21% YTD: Should You Buy, Hold or Sell the Stock? — Negative

MRK   Zacks Investment Research — May 26, 2025

Merck stock lags industry as Keytruda dependency, Gardasil woes in China, and tariff risks cloud outlook despite pipeline strength and new launches.

image for news MRK Down 21% YTD: Should You Buy, Hold or Sell the Stock?

Transaction in Own Shares — Neutral

SHEL   GlobeNewsWire — May 26, 2025

Transaction in Own Shares 26 May, 2025 • • • • • • • • • • • • • • • • Shell plc (the ‘Company') announces that on 26 May, 2025 it purchased the following number of Shares for cancellation. Aggregated information on Shares purchased according to trading venue: Date of purchase Number of Shares purchased Highest price paid Lowest price paid Volume weighted average price paid per share Venue Currency 26/05/2025 399,111 €29.3700 €29.1950 €29.2828 XAMS EUR 26/05/2025 155,116 €29.3700 €29.2000 €29.2831 CBOE DXE EUR 26/05/2025 60,773 €29.3700 €29.2000 €29.2902 TQEX EUR These share purchases form part …

image for news Transaction in Own Shares

Wall Street sets Lucid stock price for next 12 months — Neutral

LCID   Finbold — May 26, 2025

Wall Street analysts are holding a slightly bearish outlook on Lucid's (NASDAQ: LCID) stock over the next year as the equity continues to experience increased volatility.

image for news Wall Street sets Lucid stock price for next 12 months

Shares of Amazon.com Inc. (NASDAQ: AMZN) slipped by 0.3% over the past five trading sessions, briefly muting a rally that's seen the stock gain 11.58% over the past month.

image for news Amazon Stock (NASDAQ: AMZN) Price Prediction and Forecast 2025-2030 for May 26

Shares of Palantir Technologies Inc. (NASDAQ:PLTR) were mostly flat over the past five trading sessions, falling by 0.10%.

image for news Palantir Technologies (NASDAQ: PLTR) Price Prediction and Forecast 2025-2030 for May 26

Best Natural and Organic Food Stocks to Keep an Eye On in 2025 — Positive

BYND  GIS  SFM  UNFI   Zacks Investment Research — May 26, 2025

Sprouts Farmers, United Natural, Beyond Meat and General Mills are betting big on organic, clean-label foods and redefining what's healthy on store shelves.

image for news Best Natural and Organic Food Stocks to Keep an Eye On in 2025

Dycom Jumps 39% in 3 Months: Should You Buy, Sell or Hold the Stock? — Positive

DY   Zacks Investment Research — May 26, 2025

DY gains from fiber-to-the-home programs and hyperscaler projects, offsetting macro and tariff headwinds with strong long-term growth visibility.

image for news Dycom Jumps 39% in 3 Months: Should You Buy, Sell or Hold the Stock?

Should You Buy MRK Stock At $80? — Negative

MRK   Forbes — May 26, 2025

Merck (NYSE:MRK) stock has experienced a significant 22% decline this year, sharply underperforming the broader S&P 500 index, which is down only 1%. This downturn can be attributed to several factors: a lowered guidance for 2025 and growing concerns about the long-term growth prospects of its blockbuster drugs, Keytruda and Gardasil.

image for news Should You Buy MRK Stock At $80?

NEW YORK CITY, NY / ACCESS Newswire / May 25, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of DoubleVerify Holdings, Inc. (NYSE: DV) between November 10, 2023 and February 27, 2025, both dates inclusive (the "Class Period"). If you wish to serve as lead plaintiff, you must move the Court no later than July 21, 2025.

image for news ROSEN, TRUSTED INVESTOR COUNSEL, Encourages DoubleVerify Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DV

NEW YORK CITY, NY / ACCESS Newswire / May 26, 2025 / WHY: New York, N.Y., May 26, 2025.

image for news ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Open Lending Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - LPRO

NEW YORK CITY, NY / ACCESS Newswire / May 26, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Treace Medical Concepts, Inc. (NASDAQ:TMCI) between May 8, 2023 and May 7, 2024, both dates inclusive (the "Class Period"), of the important June 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Treace Medical securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

image for news ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Treace Medical Concepts, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TMCI

NEW YORK CITY, NY / ACCESS Newswire / May 26, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of West Pharmaceutical Services, Inc. (NYSE:WST) between February 16, 2023 and February 12, 2025, both dates inclusive (the "Class Period"), of the important July 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased West common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

image for news ROSEN, NATIONAL TRIAL LAWYERS, Encourages West Pharmaceutical Services, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - WST

Gorilla Pops 14.6% on Buyback Completion: Should You Buy GRRR Now? — Positive

GRRR   Zacks Investment Research — May 26, 2025

GRRR rallies after completing $5.4M in buybacks and lifting insider ownership to 20%, with 2025 growth and margins tracking higher.

image for news Gorilla Pops 14.6% on Buyback Completion: Should You Buy GRRR Now?

Wix Acquires Hour One to Boost Generative AI and Drive Innovation — Positive

WIX   Zacks Investment Research — May 26, 2025

WIX acquires Hour One to scale AI media creation, boost immersive web design and cut reliance on third parties for front-end innovation.

image for news Wix Acquires Hour One to Boost Generative AI and Drive Innovation

Cautious Optimism in Gap's Pre-Q1 Earnings: Buy or Hold for Now? — Positive

GAP   Zacks Investment Research — May 26, 2025

GAP expects modest Q1 growth, margin expansions and brand momentum, with cost controls helping offset macro and tariff headwinds in the upcoming report.

image for news Cautious Optimism in Gap's Pre-Q1 Earnings: Buy or Hold for Now?

CrowdStrike: Don't Chase, As Q1 Results Are Unlikely To Be Stellar — Positive

CRWD   Seeking Alpha — May 26, 2025

CrowdStrike has outperformed both the market and cybersecurity peers quite handsomely this year, with the sustainability of this alpha likely to be dictated by Q1 earnings on the 3rd of June. The pace of sales growth is expected to dip even further, but the decline in new ARR may not be as bad as what was seen in H2-25. CRWD is due to face pressure on the operational margin front, as it ramps up investments and incurs one-off costs.

image for news CrowdStrike: Don't Chase, As Q1 Results Are Unlikely To Be Stellar